TRANSMEDICS GROUP INC (TMDX) Fundamental Analysis & Valuation

NASDAQ:TMDX • US89377M1099

Current stock price

101.26 USD
-6.86 (-6.34%)
At close:
102.16 USD
+0.9 (+0.89%)
Pre-Market:

This TMDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. TMDX Profitability Analysis

1.1 Basic Checks

  • In the past year TMDX was profitable.
  • In the past year TMDX had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: TMDX reported negative net income in multiple years.
  • In multiple years TMDX reported negative operating cash flow during the last 5 years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 17.81%, TMDX belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.
  • TMDX has a better Return On Equity (40.22%) than 98.40% of its industry peers.
  • TMDX has a Return On Invested Capital of 8.76%. This is amongst the best in the industry. TMDX outperforms 86.63% of its industry peers.
  • TMDX had an Average Return On Invested Capital over the past 3 years of 4.27%. This is below the industry average of 9.12%.
  • The last Return On Invested Capital (8.76%) for TMDX is above the 3 year average (4.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROIC 8.76%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300 400

1.3 Margins

  • With an excellent Profit Margin value of 31.43%, TMDX belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
  • The Operating Margin of TMDX (17.93%) is better than 89.30% of its industry peers.
  • With a Gross Margin value of 59.92%, TMDX perfoms like the industry average, outperforming 59.89% of the companies in the same industry.
  • TMDX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TMDX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TMDX is still creating some value.
  • Compared to 1 year ago, TMDX has more shares outstanding
  • The number of shares outstanding for TMDX has been increased compared to 5 years ago.
  • The debt/assets ratio for TMDX has been reduced compared to a year ago.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • TMDX has an Altman-Z score of 4.68. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
  • TMDX has a Altman-Z score of 4.68. This is in the better half of the industry: TMDX outperforms 75.94% of its industry peers.
  • The Debt to FCF ratio of TMDX is 3.84, which is a good value as it means it would take TMDX, 3.84 years of fcf income to pay off all of its debts.
  • TMDX's Debt to FCF ratio of 3.84 is fine compared to the rest of the industry. TMDX outperforms 78.61% of its industry peers.
  • A Debt/Equity ratio of 1.06 is on the high side and indicates that TMDX has dependencies on debt financing.
  • TMDX has a Debt to Equity ratio of 1.06. This is in the lower half of the industry: TMDX underperforms 78.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Altman-Z 4.68
ROIC/WACC1.09
WACC8.05%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • TMDX has a Current Ratio of 7.14. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 7.14, TMDX belongs to the best of the industry, outperforming 86.10% of the companies in the same industry.
  • A Quick Ratio of 6.59 indicates that TMDX has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 6.59, TMDX belongs to the best of the industry, outperforming 86.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.14
Quick Ratio 6.59
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TMDX Growth Analysis

3.1 Past

  • TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 178.22%, which is quite impressive.
  • TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.13%.
  • The Revenue has been growing by 88.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%

3.2 Future

  • TMDX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.71% yearly.
  • Based on estimates for the next years, TMDX will show a quite strong growth in Revenue. The Revenue will grow by 18.03% on average per year.
EPS Next Y-11.67%
EPS Next 2Y14.76%
EPS Next 3Y19.73%
EPS Next 5Y18.71%
Revenue Next Year22.82%
Revenue Next 2Y20.77%
Revenue Next 3Y18.99%
Revenue Next 5Y18.03%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. TMDX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 36.04 indicates a quite expensive valuation of TMDX.
  • Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 68.98% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.91. TMDX is valued slightly more expensive when compared to this.
  • The Price/Forward Earnings ratio is 40.79, which means the current valuation is very expensive for TMDX.
  • Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than 68.45% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.99. TMDX is valued rather expensively when compared to this.
Industry RankSector Rank
PE 36.04
Fwd PE 40.79
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than the industry average as 71.66% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TMDX indicates a rather cheap valuation: TMDX is cheaper than 80.75% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 26.18
EV/EBITDA 25.94
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of TMDX may justify a higher PE ratio.
  • A more expensive valuation may be justified as TMDX's earnings are expected to grow with 19.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.76%
EPS Next 3Y19.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TMDX Dividend Analysis

5.1 Amount

  • No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TMDX Fundamentals: All Metrics, Ratios and Statistics

TRANSMEDICS GROUP INC

NASDAQ:TMDX (4/28/2026, 8:02:34 PM)

Premarket: 102.16 +0.9 (+0.89%)

101.26

-6.86 (-6.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength10.56
Industry Growth62.11
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners111.22%
Inst Owner Change0.07%
Ins Owners2.98%
Ins Owner Change1.41%
Market Cap3.50B
Revenue(TTM)605.49M
Net Income(TTM)190.29M
Analysts83
Price Target162.18 (60.16%)
Short Float %22.77%
Short Ratio8.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.66%
Min EPS beat(2)32.92%
Max EPS beat(2)84.39%
EPS beat(4)4
Avg EPS beat(4)96.18%
Min EPS beat(4)32.92%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)170.32%
EPS beat(12)10
Avg EPS beat(12)118.73%
EPS beat(16)13
Avg EPS beat(16)92.69%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)1.22%
Revenue beat(4)3
Avg Revenue beat(4)4.11%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)5.48%
Revenue beat(12)10
Avg Revenue beat(12)10.09%
Revenue beat(16)14
Avg Revenue beat(16)16.58%
PT rev (1m)8.9%
PT rev (3m)8.97%
EPS NQ rev (1m)1.32%
EPS NQ rev (3m)-11.62%
EPS NY rev (1m)-5.06%
EPS NY rev (3m)-15.99%
Revenue NQ rev (1m)-0.93%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)1.88%
Valuation
Industry RankSector Rank
PE 36.04
Fwd PE 40.79
P/S 5.78
P/FCF 26.18
P/OCF 18.14
P/B 7.39
P/tB 7.61
EV/EBITDA 25.94
EPS(TTM)2.81
EY2.78%
EPS(NY)2.48
Fwd EY2.45%
FCF(TTM)3.87
FCFY3.82%
OCF(TTM)5.58
OCFY5.51%
SpS17.53
BVpS13.7
TBVpS13.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.4279 (-70.94%)
Profitability
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROCE 11.09%
ROIC 8.76%
ROICexc 17.48%
ROICexgc 17.98%
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
FCFM 22.06%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
ROICexc(3y)8.3%
ROICexc(5y)N/A
ROICexgc(3y)8.55%
ROICexgc(5y)N/A
ROCE(3y)5.4%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Debt/EBITDA 3.7
Cap/Depr 217.96%
Cap/Sales 9.79%
Interest Coverage 10.15
Cash Conversion 142.04%
Profit Quality 70.2%
Current Ratio 7.14
Quick Ratio 6.59
Altman-Z 4.68
F-Score7
WACC8.05%
ROIC/WACC1.09
Cap/Depr(3y)910.54%
Cap/Depr(5y)653.45%
Cap/Sales(3y)34%
Cap/Sales(5y)25.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
EPS Next Y-11.67%
EPS Next 2Y14.76%
EPS Next 3Y19.73%
EPS Next 5Y18.71%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%
Revenue Next Year22.82%
Revenue Next 2Y20.77%
Revenue Next 3Y18.99%
Revenue Next 5Y18.03%
EBIT growth 1Y189.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60%
EBIT Next 3Y45.75%
EBIT Next 5Y47.11%
FCF growth 1Y265.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y295.14%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSMEDICS GROUP INC / TMDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to TMDX.


Can you provide the valuation status for TRANSMEDICS GROUP INC?

ChartMill assigns a valuation rating of 4 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.


Can you provide the profitability details for TRANSMEDICS GROUP INC?

TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 6 / 10.


What are the PE and PB ratios of TRANSMEDICS GROUP INC (TMDX) stock?

The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 36.04 and the Price/Book (PB) ratio is 7.39.


Can you provide the expected EPS growth for TMDX stock?

The Earnings per Share (EPS) of TRANSMEDICS GROUP INC (TMDX) is expected to decline by -11.67% in the next year.